Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma

Current Oncology

Volumn 20, Issue 6, 2013, Pages

  Yildiz, I ^a   Sen, F ^a   Kilic, L ^a   Ekenel, M ^a   Ordu, C ^a   Kilicaslan, I ^a   Darendeliler, E ^a   Tunc, H M ^a   Varol, U ^b   Bavbek, S ^a   Basaran, M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

First line therapy; Metastatic renal cell carcinoma; Prognostic factors; Sarcomatoid features; Vascular endothelial growth factor; VEGF antagonist

Indexed keywords

LACTATE DEHYDROGENASE; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYPERTENSION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84890047585     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1596     Document Type: Article

References (23)

1. Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist 2011;16(suppl 2):1-3.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
3. Mendel DB, Laird AD, Xin X, et al. In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
4. Hutson TE, Figlin RA. Novel therapeutics for metastatic renal cell carcinoma. Cancer 2009;115(suppl):2361-7.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
6. Yildiz I, Sen F, Basaran M, et al. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. Jpn J Clin Oncol 2011;41:1380-7.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
8. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
10. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
11. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543-50.
12. Yuasa T, Tsuchiya N, Urakami S, et al. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int 2012;109:1349-54.
13. Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22:295-300.
14. Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer 2008;6(suppl 1):S7-13.
15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
16. Choueiri TK, Vaziri SA, Jaeger E, et al. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-5.
17. Anglesio MS, George J, Kulbe H, et al. il6-stat3-hif signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011;17:2538-48.
18. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827-37.
19. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170:1742-6.
20. Sandhu DP, Munson KW, Harrop JS, Hopton MR, Ratcliffe WA. Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein. Br J Urol 1993;72:848-50.
21. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997-2005.
22. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006;107:1793-800.
23. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009;27:235-41.